Sunshine Biopharma Inc(SBFM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -204.52 | Insider Own | 78.11% | Shs Outstand | 0.8M | Perf Week | -0.3% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | 79.49% | Insider Trans | - | Shs Float | 0.2M | Perf Month | -78.46% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | -3.4 | Inst Own | 7.34% | Short Float | 24.73% | Perf Quarter | -85.77% |
| Income | -0.01B | P/S | 0.07 | EPS this Y | 86.46% | Inst Trans | 6.83% | Short Ratio | 0.14 | Perf Half Y | -98.27% |
| Sales | 0.04B | P/B | 0.01 | EPS next 5Y | - | ROA | -17.78% | Short Interest | 0.04M | Perf YTD | -98.65% |
| Book/sh | 230.48 | P/C | 0.18 | EPS past 3/5Y | 92.58% 80.76% | ROE | -21.92% | 52W High | -99.28% ($464.00) | Perf Year | -99.05% |
| Cash/sh | 18.04 | P/FCF | - | Sales past 3/5Y | 102.91% 247.73% | ROIC | -20.82% | 52W Low | 29.06% ($2.58) | Perf 3Y | -100% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 60.85% | Gross Margin | 29.31% | Volatility(W/M) | 20.89% 31.84% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | -0.3 | Sales Y/Y TTM | -2.74% | Oper. Margin | -14.71% | ATR (14) | 1.7 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 3.3 | EPS Q/Q | 70.91% | Profit Margin | -16.5% | RSI (14) | 28.3 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.46 | Sales Q/Q | -1.56% | SMA20 | -42.41% ($5.78) | Beta | 1.43 | Target Price | $1120 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/08/05 | SMA50 | -77.14% ($14.57) | Rel Volume | 0.62 | Prev Close | $3.11 |
| Employees | 50 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | 4.17% 6.9% | SMA200 | -96.98% ($110.26) | Avg Volume(3M) | 0.30M | Price | $3.33 |
| IPO | 2009/10/30 | Option/Short | No/No | Trades | 1960 | Volume | 183,387 | Change | 7.07% |
💊 Sunshine Biopharma () is a US-listed micro-cap pharmaceutical company that sells prescription generics and biosimilars through its Canadian generic-drug subsidiary Nora Pharma, while independently developing its own anti-cancer candidate 'Adva-27a' and other compounds. Generic-drug sales make up the core of its main business, with its in-house new-drug pipeline serving as an additional upside factor for the stock.
Over the past 1 year, on the lower side
99% below its 1-year high.
Traded less than usual. That is 62% of its average volume.
SBFM has a sound balance sheet but weak earning power
Of every $100 in sales, $14.71 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +86.5% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $7. Peers typically go for $211.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
24.7% of the float is sold short.
Tap to view numbers
It ranks #80 of 83 in the industry
Based on market cap of $3M.
RDHL#78 Redhill Biopharma Ltd ADR $4M PER - 
AKAN#79 Akanda Corp $3M PER - SBFM#80 Sunshine Biopharma Inc $3M PER - 
SXTC#81 China SXT Pharmaceuticals Inc $2M PER - 
PRFX#82 PRF Technologies Ltd $2M PER - 
FAQ
What kind of company is SBFM?
SBFM belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of SBFM?
The market cap of SBFM is approximately $3M, ranking 5,768 within its sector.
What is the 52-week high and low for SBFM?
SBFM has recorded a 52-week high of $464.00 and a low of $2.58.
